SCHEMBL1035922

SCHEMBL1035922

CS(=O)(=O)Nc1ccccc1Nc1nc(Nc2cccc(-c3cnco3)c2)ncc1F

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.63
GLO1 Q04760 4/20 0.60
PRKCQ Q04759 1/20 0.53
GSK3A P49840 1/20 0.48
LRRK2 Q5S007 1/20 0.48
MAPK15 Q8TD08 1/20 0.48
CAMKK2 Q96RR4 1/20 0.48
ALK Q9UM73 2/20 0.48
MET P08581 1/20 0.48
AURKA O14965 6/20 0.46
MAPK8 P45983 2/20 0.46
AURKB Q96GD4 1/20 0.46
CDK19 Q9BWU1 1/20 0.46
MAP3K7 O43318 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
TBK1 Q9UHD2 1/20 0.44
CDC7 O00311 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1038297 0.83 GLO1 (0.72) SYKGLO1GSK3ALRRK2MAPK15
SCHEMBL1076932 0.81 GLO1 (0.59) SYKGLO1GSK3ALRRK2MAPK15
SCHEMBL1039144 0.81 GLO1 (0.83) SYKGLO1GSK3ALRRK2MAPK15
SCHEMBL1040427 0.81 GLO1 (0.79) SYKGLO1GSK3ALRRK2MAPK15
SCHEMBL1040138 0.81 GLO1 (0.69) SYKGLO1ALKMETAURKA
SCHEMBL4008168 0.81 SYK (0.66) SYKPRKCQAURKAAURKBMAP3K7
SCHEMBL1076134 0.80 GLO1 (0.60) SYKGLO1GSK3ALRRK2MAPK15
SCHEMBL3999487 0.80 SYK (0.67) SYKPRKCQGSK3AAURKAMAPK8
SCHEMBL1037391 0.80 GLO1 (0.59) SYKGLO1GSK3ALRRK2MAPK15
SCHEMBL1039908 0.80 GLO1 (0.59) SYKGLO1GSK3ALRRK2MAPK15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US claimed
EP-2276747-A1 SULFONAMIDES AS ZAP-70 INHIBITORS Cellzome Limited (GB) 2011-01-26 EP claimed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO claimed
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US disclosed
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US disclosed
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US disclosed
EP-2276747-A1 SULFONAMIDES AS ZAP-70 INHIBITORS Cellzome Limited (GB) 2011-01-26 EP disclosed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO disclosed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS ZAP70, SYK, LCK SYK 2/4885GLO1 3741/4885PRKCQ 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.